Balance Sheet as at De	cember 31, 2016					
Particulars	Note	ZAR- Thousands INR- Thousands				
	No.	As at December 31		nber 31		
		2016	2015	2016	2015	
ASSETS:						
Non-Current Assets:						
Property, Plant and Equipment	1	-	-	-		
Other Intangible Assets	1	-	-	-		
Other Non-Current Assets	2	-	26	-	:	
Current Assets:						
Financial Assets:						
Trade Receivables	3	626	1,091	3,111	4,	
Cash and Cash Equivalents	4	58	582	288	2,	
		684	1,673	3,399	7,:	
Total		684	1,699	3,399	7,	
EQUITY AND LIABILITIES:		304	1,099	3,333		
Equity:						
Equity Share Capital	5	0	0	0		
• • •	6			_	2	
Other Equity	О	620	621	3,081	2,	
		620	621	3,081	2,	
Current Liabilities:						
Financial Liabilities:	_					
Trade Payables	7	64	1,078	318	4,	
Total		684	1,699	3,399	7,	
Significant Accounting Policies	II					
Notes to the Financial Statements	1 to 15					
Statement of Profit and Loss for the	vear ended Decem	her 31, 2016				
Particulars	Note		usands	INR- Tho	Thousands	
i di dedidio	No.	ZAR- Thousands INR- Tho Year ended December 31				
	I INO.		Year ended De	cember 31	usanus	
	NO.					
REVENUE:	No.	2016	Year ended De 2015	2016		
		2016	2015	2016	2015	
Revenue from Operations	8	2016 15,027	2015 13,982	2016 68,824	2015 70,	
Revenue from Operations Total Revenue		2016	2015	2016	2015 70,	
Revenue from Operations Total Revenue EXPENSES:	8	2016 15,027 15,027	2015 13,982 13,982	2016 68,824 68,824	2015 70,	
Revenue from Operations Total Revenue EXPENSES: Finance Costs	8	2016 15,027	2015 13,982	2016 68,824	2015 70,	
Revenue from Operations Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses	8 9 1	2016 15,027 15,027 8 -	2015 13,982 13,982 8 -	2016 68,824 68,824 37	2015 70, 70,	
Revenue from Operations Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses Other Expenses	8	2016 15,027 15,027 8 - 15,019	2015 13,982 13,982 8 - 13,972	2016 68,824 68,824 37 - 68,787	2015 70, 70,	
Revenue from Operations Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses Other Expenses Total Expenses	8 9 1	2016 15,027 15,027 8 -	2015 13,982 13,982 8 - 13,972 13,980	2016 68,824 68,824 37 - 68,787 68,824	2015 70, 70,	
Revenue from Operations Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses Other Expenses Total Expenses Profit before Tax	8 9 1	2016 15,027 15,027 8 - 15,019	2015 13,982 13,982 8 - 13,972	2016 68,824 68,824 37 - 68,787	2015 70, 70,	
Revenue from Operations Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses Other Expenses Total Expenses Profit before Tax Less: Tax Expense:	8 9 1	2016 15,027 15,027 8 - 15,019 15,027	2015 13,982 13,982 8 - 13,972 13,980 2	2016 68,824 68,824 37 - 68,787 68,824	2015 70, 70, 70,	
Revenue from Operations Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses Other Expenses Total Expenses Profit before Tax Less: Tax Expense: Current Tax	8 9 1	2016 15,027 15,027 8 - 15,019 15,027 - 1	2015 13,982 13,982 8 - 13,972 13,980 2	2016 68,824 68,824 37 - 68,787 68,824 -	2015 70, 70, 70,	
Revenue from Operations Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses Other Expenses Total Expenses Profit before Tax Less: Tax Expense: Current Tax [Loss]/ Profit for the year	8 9 1	2016 15,027 15,027 8 - 15,019 15,027	2015 13,982 13,982 8 - 13,972 13,980 2	2016 68,824 68,824 37 - 68,787 68,824	2015 70, 70,	
Revenue from Operations Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses Other Expenses Total Expenses Profit before Tax Less: Tax Expense: Current Tax [Loss]/ Profit for the year	8 9 1	2016 15,027 15,027 8 - 15,019 15,027 - 1	2015 13,982 13,982 8 - 13,972 13,980 2	2016 68,824 68,824 37 - 68,787 68,824 -	2015 70, 70, 70, 70,	
Revenue from Operations Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses Other Expenses Total Expenses Profit before Tax Less: Tax Expense: Current Tax [Loss]/ Profit for the year	8 9 1	2016 15,027 15,027 8 - 15,019 15,027 - 1	2015 13,982 13,982 8 - 13,972 13,980 2 - 2	2016 68,824 68,824 37 - 68,787 68,824 -	2015 70, 70, 70, 70,	
Revenue from Operations Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses Other Expenses Total Expenses Profit before Tax Less: Tax Expense: Current Tax [Loss]/ Profit for the year OTHER COMPREHENSIVE INCOME: Other Comprehensive Income for the year, net of tax	8 9 1	2016 15,027 15,027 8 - 15,019 15,027 - 1 (1)	2015 13,982 13,982 8 - 13,972 13,980 2	2016 68,824 68,824 37 - 68,787 68,824 -	2015 70, 70, 70,	
Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses Other Expenses Total Expenses Profit before Tax Less: Tax Expense: Current Tax [Loss]/ Profit for the year OTHER COMPREHENSIVE INCOME:	8 9 1	2016 15,027 15,027 8 - 15,019 15,027 - 1 (1)	2015 13,982 13,982 8 - 13,972 13,980 2 - 2	2016 68,824 68,824 37 - 68,787 68,824 - 5 (5)	2015 70,4 70,4 70,4	
Revenue from Operations Total Revenue EXPENSES: Finance Costs Depreciation, Amortisation and Impairment expenses Other Expenses Total Expenses Profit before Tax Less: Tax Expense: Current Tax [Loss]/ Profit for the year OTHER COMPREHENSIVE INCOME: Other Comprehensive Income for the year, net of tax Total Comprehensive Income for the year	8 9 1 10	2016 15,027 15,027 8 - 15,019 15,027 - 1 (1)	2015 13,982 13,982 8 - 13,972 13,980 2 - 2	2016 68,824 68,824 37 - 68,787 68,824 - 5 (5)	2015 70, 70, 70, 70,	

As per our report of even date For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number: 106625W

Chandresh S. Shah

For and on behalf of the Board

Director

Partner

Membership Number: 042132 Ahmedabad, Dated: May 25, 2017

	Script Management Services (Pty) Ltd.				
	Statement of Change in Equity for the year ended Decen	nber 31, 2016			,
а	Equity Share Capital:		No. of Shares	ZAR- Thousands	INR- Thousands
	Ordinary Shares of Currency ZAR 1/- each, Issued, Subscribed and Fully Paid-up:				
	As at December 31, 2014 [ZAR 1/-]		1	0	0
	As at December 31, 2015 [ZAR 1/-]		1	0	0
	As at December 31, 2016 [ZAR 1/-]		1	0	0
				AR- Thousand	S
b	b Other Equity:		Securities Premium Reserve	Retained Earnings	Total
	As at December 31, 2014		300	319	619
	Add: Profit for the year			2	2
	As at December 31, 2015		300	321	621
	Less: Loss for the year			(1)	(1)
	As at December 31, 2016		300	320	620
					-
			INR- Thou	•	
b	Other Equity:	Foreign Currency Translation Reserve	Securities Premium Reserve	Retained Earnings	Total
	As at December 31, 2014	-	1,287	1,805	3,092
	Add: Profit for the year		,	. 11	11
	Less: Deduction for the year #	(438)			(438)
	As at December 31, 2015	(438)	1,287	1,816	2,665
	Add: Profit for the year	` ,	,	(5)	(5)
	Add: Addition for the year #	217		()	217
	As at December 31, 2016	(221)	1,287	1,811	2,877
	# Includes adjustments on account of exchange rate translation differences.			,	_
	For Mukesh M. Shah & Co.		For and on beha	olf of the Board	
	Chartered Accountants		TOT GITG OIT BETTE	in or the board	
	Firm Registration Number: 106625W				
	Chandresh S. Shah Partner Membership Number: 042132 Ahmedabad, Dated: May 25, 2017			Director	

Script Management Services (Pty) Ltd.

I-Company overview:

Script Management Services [the Company] was incorporated on October 14, 2009. The Company's registered office is situated at Southdown Office Park, Building B, Centurion, Pretoria - 0157. The principal activity of the company is to carry out data extraction of dispensed medicines by pharmacies and to analyse and generate the reports.

II-Significant Accounting Policies:

1 Basis of Accounting:

The annual financial statements have been prepared in accordance with the International Financial Reporting Standards for Small and Medium - sized Entities, and the Companies Act 71 of 2008. The financial statements have been prepared on historical cost basis, and incorporate the principal accounting policies set out below. These accounting policies are consistent with the previous year.

2 Reporting Currency Translation:

The Local accounts are maintained in local and functional currency which is "South African Rand [ZAR]". These accounts have been translated in Indian Rupees considering the operation of the Company as "Non-integral operations" for holding company. The translation of Financial Statements to Indian Rupee [INR] from "ZAR" is performed for assets and liabilities using the exchange rates prevailing on the Balance sheet dates and for revenues and expenses using the average exchange rates for the respective periods. The gain or loss resulting from such translation is included in "Foreign Currency Translation Reserve" under Other Equity.

3 Property, Plant and Equipment:

- A Property, plant and equipment are tangible items that are held for use in the production or supply of goods or services, for rental to others or for administrative purposes and are expected to be used during more than one year.
- B Property, plant and equipment is carried at cost less accumulated depreciation and accumulated impairment losses.
- C Costs include costs incurred initially to acquire or construct an item of property, plant and equipment and costs incurred subsequently to add to, replace part of, or service it. If a replacement cost is recognised in the carrying amount of an item of property, plant and equipment, the carrying amount is derecognised.
- **D** Depreciation is provided using the straight line method to write down the cost, less estimated residual value over the useful life of the property, plant and equipment which is as follows:

 Item
 Average useful life

 IT Equipment
 3 years

- **E** The residual value, depreciation and the useful life of each asset are reviewed at each annual reporting year if there are indicators present that there has been a change from the previous estimate.
- F Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss in the year.

4 Intangible Assets:

- **A** An intangible asset is an identifiable non-monetary asset without physical substance.
- **B** Intangible assets are initially recognised at cost.
- C All research and development costs are recognised as an expense unless they form part of the cost of another asset that meets the recognition criteria.
- **D** Intangible assets are carried at cost less any accumulated amortisation and any impairment losses.
- E If the company is unable to make a reliable estimate of the useful life of an intangible assets, the life will be presumed to be 10 years.
- **F** The amortisation period and the amortisation for intangible assets are reviewed at each reporting year date if there are indicators present that there is a change from the previous estimate.
- G Amortisation is provided to write down the intangible assets, on a straight line basis, to their residual values as follows:

em Average useful life

Patents, Trademarks and other rights 3 years

5 Financial instruments:

Financial instruments at amortised cost

These include loans, trade receivables and trade payables. Those debt instruments which meet the criteria in section 11.8(b) of the standard, are subsequently measured at amortised cost using the effective interest method. Debt instruments which are classified as current assets or current liabilities are measured at the undiscounted amount of the cash expected to be received or paid, unless the arrangement effectively constitutes a financing transaction.

At each reporting date, the carrying amounts of assets held in this category are reviewed to determine whether there is any objective evidence of impairment. If there is objective evidence, the recoverable amount is estimated and compared with the carrying amount. If the estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in profit or loss.

6 Taxes on Income:

- **A** Current tax for current and prior periods is, to the extent unpaid, recognised as a liability. If the amount already paid in respect of current and prior periods exceeds the amount due for those periods, the excess is recognised as an asset.
- **B** A deferred tax liability is recognised for all taxable temporary differences. A deferred tax asset is recognised for all deductible temporary differences and for the carry forward of unused tax losses and unused tax credits. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the reporting date.

7 Impairment of assets:

- **A** The company assesses at each reporting date whether there is any indication that an asset may be impaired.
- **B** If there is any indication that an asset may be impaired, the recoverable amount is estimated for the individual asset. If it is not possible to estimate the recoverable amount of the individual asset, the recoverable amount of the cash generating unit to which the assets belongs is determined.
- C If an impairment loss subsequently reverses, the carrying amount of the asset (or group of related assets) is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss been recognised for the asset [or group of assets] in prior years. A reversal of impairment is recognised immediately in profit or loss.

8 Revenue Recognition:

Revenue from the sale of goods is recognised when all the following conditions have been satisfied:

- **A** the company has transferred to the buyer the significant risks and rewards of ownership of the goods.
- **B** the company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold. The amount of revenue can be measured reliably.
- C it is probable that the economic benefits associated with the transaction will flow to the company; and
- **D** the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Script Management Services (Pty) Ltd.

II-Significant Accounting Policies- Continued:

When the outcome of a transaction involving the rendering of services can be estimated reliably, revenue associated with the transaction is recognised by reference to the stage of completion of the transaction at the balance sheet date. The outcome of a transaction can be estimated reliably when all the following conditions are satisfied:

- A The amount of revenue can be measured reliably;
- **B** It is probable that the economic benefits associated with the transaction will flow to the company;
- C The stage of completion of the transaction at the balance sheet date can be measured reliably; and
- **D** The costs incurred for the transaction and the costs to complete the transaction can be measured reliably.

When the outcome of the transaction involving the rendering of services cannot be estimated reliably, revenue is recognised only to the extent of the express recognised that are recoverable. Revenue is measured at the fair value of the consideration received or receivable and represent the amounts receivable for goods and services provided in the normal course of business, net of trade discounts and volume rebates, and value added tax. Interest is recognised, in statement of Profit and Loss, using the effective interest rate method.

9 Borrowing costs:

Borrowing costs are recognised as an expense in the year in which they are incurred.

Notes to the Financial Statements

Note: 1: Property, Plant a	nd Equipment & Intagible Assets:
----------------------------	----------------------------------

	Property Plant and Equipmen				
	Office Equipment		Brands/ Trademark		
Gross Block:	ZAR-	INR-	ZAR-	INR-	
GIOSS DIOCK.	Thousands	Thousands	Thousands	Thousands	
As at December 31, 2014	26	142	230	1,258	
Additions		-		-	
Disposals		-		-	
Other adjustments		(30)		(271)	
As at December 31, 2015	26	112	230	987	
Additions		-		-	
Disposals		-		-	
Other adjustments		17		156	
As at December 31, 2016	26	129	230	1,143	
Depreciation and Impairment:					
As at December 31, 2014	26	142	230	1,258	
Charge for the year		-		-	
Impairment for the year		-		-	
Disposals		-		-	
Other adjustments		(30)		(271)	
As at December 31, 2015	26	112	230	987	
Charge for the year		-		-	
Impairment for the year		-		-	
Disposals		-		-	
Other adjustments		17		156	
As at December 31, 2016	26	129	230	1,143	
Net Block:					
As at December 31, 2015	-	-	-	-	
As at December 31, 2016	-	-	-	-	
Note: Other adjustments include adjustments on account of exchange rate translation differences.					

Notes to the Financial Statements	ZAR- Thousands		INR- Thousands	
	ZAK- IIIC	As at Decen		usanus
	2016	2015	2016	2015
Note: 2-Other Non-Current Assets:				
[Unsecured, Considered Good unless otherwise stated]		26		110
Balances with Statutory Authorities Total	-	26 26		112 112
Iotal		20	_	112
Note: 3-Trade Receivables:				
Others- Considered good [Unsecured]	626	1,091	3,111	4,680
Total	626	1,091	3,111	4,680
Note: 4-Cash and Cash Equivalents:				
Balances with Banks	58	582	288	2,497
Total	58	582	288	2,497
Note: 5-Equity Share Capital:				
Authorised:				
1 [as at December 31, 2015: 1] Ordinary Share of ZAR 1/- each]	0	0	0	0
	0	0	0	0
Issued, Subscribed and Fully Paid-up Equity Shares:				
1 [as at December 31, 2015: 1] Ordinary Share of ZAR 1/- each, fully paid-up	0	0	0	0
[ZAR 1/- (as at December 31, 2015: ZAR 1/-)]	0	0	0	0
A There is no change in the number of shares as at the beginning and end of the year.				
Number of shares at the beginning and at the end of the year	1	1		
B Ordinary share of ZAR 1/- each, fully paid held by holding company, Zydus	_	-		
Healthcare SA (Pty) Limited, a company incorporated in South Africa which is a subsidiary				
company of Zydus International Private Limited, [Refer Note 14] a company incorporated				
in the Republic of Ireland which is a subsidiary company of Cadila Healthcare Limited, the				
ultimate holding company, a company incorporated in India.				
Number of Shares	1	1		
% to total share holding	100%	100%		
Note: 6-Other Equity:				
Other Reserves:				
Securities Premium Reserve:				
Balance as per last Balance Sheet	300	300	1,491	1,287
Foreign Currency Translation Reserve:				
Balance as per last Balance Sheet			(438)	- (420
Less [Add]: Exchange Rate differences on translation to INR	_	_	(221)	(438 (438
Retained Earnings:			(221)	(+50
Balance as per last Balance Sheet	321	319	1,816	1,805
[Less]/ Add: [Loss]/ Profit for the year	(1)	2	(5)	11
Balance as at the end of the year	320	321	1,811	1,816
Total	620	621	3,081	2,665
Note: 7-Trade Payables: Trade Payables	64	1,078	318	4,624
Total Total	64	1,078	318	4,624
	ZAR- The		INR- Tho	usands
	2016	Year ended De 2015	2016	2015
Note: 8-Revenue from Operations:				
Data fees income	14,983	13,944	68,622	70,278
Key account management fees	44	38	202	192
Total	15,027	13,982	68,824	70,470
Note: 9-Finance Cost:				
Bank commission & charges	8	8	37	40
Total	8	8	37	40
Note: 10-Other Expenses:				
	14,983	13,944	68,622	70,278
Data fees and 11 vendor data expenses	- T/JUJ	10,011	30,322	-
Data fees and IT Vendor data expenses Miscellaneous Expenses - Payment to the auditors as "Auditor"	7	28	165	141
Miscellaneous Expenses - Payment to the auditors as "Auditor" Total	36 15,019	28 13,972	165 68,787	70,419

Script Management Services (Pty) Ltd. **Notes to the Financial Statements** Note: 11-Calculation of Earnings per Equity Share [EPS]: The numerators and denominators used to calculate the basic and diluted EPS are as follows: A [Loss]/ Profit attributable to Shareholders (1) 2 (5) 11 B Basic and weighted average number of Equity shares outstanding during the year ZAR INR C Nominal value of equity share 1 D Basic & Diluted EPS (1000) 2000 (5000) 11000

Note: 12-Segment Information:

The Chief Operating Decision Maker [CODM] review the Company as a single segment, namely "Extraction, analysis and reporting of data related to dispensed medicines by pharmacies".

Note: 13-Related Party Transactions:

A Name of the Related Parties and Nature of the Related Party Relationship:

a Holding Company: Zydus Healthcare S.A. (Pty) Ltd [South Africa]

b Holding Company of Holding Company: Zydus International Private Limited [Ireland] [Refer Note 14] Cadila Healthcare Limited, a company incorporated in India

c Ultimate Holding Company:

d Fellow Subsidiaries:

Dialforhealth India Limited Zydus Nikkho Farmaceutica Ltda. [Brazil] Dialforhealth Unity Limited Laboratorios Combix S.L. [Spain] Dialforhealth Greencross Limited Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [USA] Zvdus Wellness Limited

M/s. Zydus Wellness-Sikkim, a Partnership Firm Simayla Pharmaceuticals (Pty) Ltd [South Africa] Alidac Healthcare (Myanmar) Limited [Myanmar] Zydus Healthcare Limited Zvdus Technologies Limited Zydus Pharmaceuticals Mexico SA De CV [Mexico]

Liva Pharmaceuticals Limited Etna Biotech S.R.L. [Italy] ZAHL B.V. [the Netherlands] Alidac Pharmaceuticals Limited Zydus Netherlands B.V. [the Netherlands] ZAHL Europe B.V. [the Netherlands] Zydus Healthcare (USA) LLC [USA] Bremer Pharma GmbH [Germany] Zydus Healthcare Philippines Inc [Philippines] Nesher Pharmaceuticals (USA) LLC [USA]

Zydus Worldwide DMCC [Dubai] [Refer Note 13] Zydus France, SAS [France]

Zydus Pharma Japan Co. Ltd. [Japan] [Liquidated during the year] Zydus Discovery DMCC [Dubai] Zydus Lanka (Private) Limited [Srilanka] Zydus Pharmaceuticals Mexico Services Company SA De C.V. [Mexico] Zydus Pharmaceuticals (USA) Inc.[USA]

e Directors:

Mr. G. Jain [Resigned w.e.f. February 24, 2016] Mr. S.R.Gadhia [Appointed w.e.f. February 24, 2016] Mr. Vineet Shiva [Appointed w.e.f. February 24, 2016] Mrs. I.F.Oliver

Transactions with Related Parties:

The following transactions were carried out with the related parties in the ordinary course of business:

a Details relating to parties referred to in items 13- A [a].

Nature of Transactions	Year ended December 31			
	<u>2016</u>	<u>2015</u>	<u>2016</u>	<u>2015</u>
Service Income:				
Data Fees	14,983	13,944	68,622	70,278
Key Account Management Fees	44	38	202	192
		As at Decer	<u>mber 31</u>	
	<u>2016</u>	<u>2015</u>	<u>2016</u>	<u>2015</u>
Outstanding:				
Receivable	626	1,091	3,111	4,680
b There are no transactions with the parties referred to in item no 13A [b, c, d & e].				

ZAR- Thousands

INR- Thousands

Note: 14 Post reporting date events :

Pursuant to the Share Purchase Agreement ['SPA'] entered into by Zydus International Private Limited [ZIPL], Ireland [wholly owned subsidiary of Cadila Healthcare Limited [CHL], India] on March 24, 2017 with Zydus Worldwide DMCC [ZWD], Dubai [wholly owned subsidiary of CHL], ZWD had acquired 100% of the share capital of Zydus Healthcare SA (Pty) Ltd [ZHSA], South Africa, for Cash Consideration. Pursuant to this, ZHSA has become direct overseas subsidiary of ZWD and the Company has become step down subsidiary of ZWD. CHL continues to be the ultimate holding company of the Company.

Note: 15

Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure.

Signatures to Significant Accounting Policies and Notes 1 to 15 to the Financial Statements

As per our report of even date For and on behalf of the Board For Mukesh M. Shah & Co.

Firm Registration Number: 106625W

Chandresh S. Shah

Chartered Accountants

Director Partner

Membership Number: 042132 Ahmedabad, Dated: May 25, 2017

Script Management Services (Pty) Ltd. Cash Flow Statement for the year ended December 31, 2016					
					Particulars
		Year ended I	December 31		
	2016	2015	2016	2015	
A Cash flows from operating activities:					
Profit before tax	-	2	-	11	
Operating profit before working capital changes	-	2	-	11	
Adjustments for:					
Decrease in trade receivables	465	802	2,130	4,042	
Decrease/ [Increase] in other current assets	26	(14)	119	(71)	
[Decrease] in trade payables	(1,014)	(222)	(4,644)	(1,119)	
Total	(523)	566	(2,395)	2,852	
Cash generated from operations	(523)	568	(2,395)	2,863	
Direct taxes paid [Net of refunds]	(1)	(2)	(5)	(11)	
Net cash from [used] operating activities	(524)	566	(2,400)	2,852	
B Cash flows from investing activities:					
Net cash used [from] in investing activities	-	-	-	-	
C Cash flows from financing activities:					
Net cash used [from] in financing activities	-	-	-	-	
Net increase in cash and cash equivalents	(524)	566	(2,400)	2,852	
Increase/ [Decrease] due to the translation to INR [Refer Note-3]	-	-	191	(443)	
Cash and cash equivalents at the beginning of the year	582	16	2,497	88	
Cash and cash equivalents at the end of the year	58	582	288	2,497	

Notes to the Cash Flow Statement

1 All figures in brackets are outflows.

- 2 Previous year's figures have been regrouped wherever necessary.
 3 Cash Flow Statement is translated into Indian Rupee [INR] at the average exchange rates for the year. The increase/ decrease resulting from such translation is shown separately as "Increase/ [Decrease] due to the translation to INR"

As per our report of even date

For and on behalf of the Board

For Mukesh M. Shah & Co., Chartered Accountants

Firm Registration Number: 106625W

Chandresh S. Shah

Partner Director

Membership Number: 042132 Ahmedabad, Dated: May 25, 2017